Sean Cassidy Biography and Net Worth

Mr. Cassidy is the Chief Financial Officer of Arvinas. He has over 20 years of experience in the life sciences industry, including serving as Chief Financial Officer of Axerion Therapeutics, a preclinical biotechnology company developing therapies for neurological diseases and injuries; Chief Financial Officer of CuraGen Corporation (NASDAQ: CRGN), a clinical stage biopharmaceutical company; and Director and Controller of 454 Life Sciences Corporation, a life sciences company that developed and commercialized next generation DNA sequencing instruments and reagents.

Earlier in his career, Mr. Cassidy served at Deloitte, one of the big four public accounting firms with a broad base of clients in the healthcare space. Mr. Cassidy is currently a board member of the Friends of Yale New Haven Children’s Hospital, a nonprofit organization that helps improve the health and well-being of pediatric patients and their families.

Mr. Cassidy holds an M.B.A. and B.S. from the University of Connecticut and is a Certified Public Accountant in the State of Connecticut.

What is Sean A. Cassidy's net worth?: The estimated net worth of Sean A. Cassidy is at least $5.75 million as of February 23rd, 2024. Mr. Cassidy owns 181,916 shares of Arvinas stock worth more than $5,748,546 as of April 26th. This net worth evaluation does not reflect any other investments that Mr. Cassidy may own. Learn More about Sean A. Cassidy's net worth.
How do I contact Sean A. Cassidy?: The corporate mailing address for Mr. Cassidy and other Arvinas executives is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. Arvinas can also be reached via phone at (203) 535-1456 and via email at [email protected]. Learn More on Sean A. Cassidy's contact information.
Has Sean A. Cassidy been buying or selling shares of Arvinas?: Sean A. Cassidy has not been actively trading shares of Arvinas in the last ninety days. Most recently, Sean A. Cassidy sold 1,702 shares of the business's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $47.05, for a transaction totalling $80,079.10. Following the completion of the sale, the chief financial officer now directly owns 181,916 shares of the company's stock, valued at $8,559,147.80. Learn More on Sean A. Cassidy's trading history.
Who are Arvinas' active insiders?: Arvinas' insider roster includes Sean Cassidy (CFO), John Houston (CEO), Bradley Margus (Director), Briggs Morrison (Director), Ronald Peck (Insider), Liam Ratcliffe (Director), Timothy Shannon (Director), and Ian Taylor (Insider). Learn More on Arvinas' active insiders.
Are insiders buying or selling shares of Arvinas?: In the last year, insiders at the sold shares 4 times. They sold a total of 9,921 shares worth more than $436,781.21. The most recent insider tranaction occured on February, 23rd when CEO John G Houston sold 5,196 shares worth more than $244,471.80. Insiders at Arvinas own 5.2% of the company. Learn More about insider trades at Arvinas.
Information on this page was last updated on 2/23/2024.

Sean A. Cassidy Insider Trading History at Arvinas

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/23/2024	Sell	1,702	$47.05	$80,079.10	181,916
3/1/2023	Sell	1,745	$29.53	$51,529.85	183,618
3/11/2022	Sell	15,000	$70.00	$1,050,000.00
3/4/2022	Sell	1,593	$63.94	$101,856.42
12/17/2021	Sell	15,000	$70.00	$1,050,000.00
7/28/2021	Sell	17,242	$100.00	$1,724,200.00	175,491
3/2/2021	Sell	2,221	$77.45	$172,016.45	160,470
2/16/2021	Sell	41,959	$78.46	$3,292,103.14	161,599
5/12/2020	Sell	10,000	$60.00	$600,000.00	150,422
3/19/2020	Sell	1,514	$37.61	$56,941.54	153,906
2/7/2020	Sell	10,000	$51.02	$510,200.00	154,517
11/19/2019	Sell	10,000	$32.00	$320,000.00	159,115
7/29/2019	Sell	11,945	$26.22	$313,197.90
10/1/2018	Buy	1,600	$16.00	$25,600.00

Sean A. Cassidy Buying and Selling Activity at Arvinas

Arvinas Company Overview

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Today's Range

Now: $32.37

$31.17

$32.72

50 Day Range

MA: $41.93

$31.60

$52.31

2 Week Range

Now: $32.37

$13.57

$53.08

Volume

778,385 shs

Average Volume

723,134 shs

Market Capitalization

$2.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.94

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>